Table 2.

Demographics and statistics of glucose and endocrine measures of 17 patients with narcolepsy compared to a group of 17 healthy controls matched for gender and age

	Narcolepsy (6 f, 11 m) Mean (SD)	Control (6 f, 11 m) Mean (SD)	P-Value	Effect Size
Age (years)	33.9 (9.0)	36.5 (9.2)	0.42	−0.2
BMI (kg/m2)	26.7 (2.9)	26.2 (2.8)	0.58	0.14
Glucose 0 Minutes (mmol/L)	5.2 (0.4)	5.3 (0.5)	0.66	−0.16
Glucose 120 Minutes (mmol/L)	5.9 (1.8)	5.9 (1.1)	0.96	0.01
AUCi (mg × min/dL)	4265 (2851)	4221 (1792)	0.96	0.01
Insulin max. (μU/mL)	105.0 (40.8)	108.6 (51.8)	0.82	−0.08
Glucose max. (mmol/L)	8.8 (1.9)	9.1 (1.8)	0.62	−0.17
HOMA2-S	59.1 (13.1)	68.8 (21.5)	0.13	−0.54
HOMA2-B	129.6 (21.5)	118.9 (34.6)	0.29	0.37
ISI	4.9. (2.4)a	4.8 (2.1)a	0.94	0.02
Insgen	1.5 (1)	1.1 (0.6)	0.13	0.54

AUCi, incremental area under the curve of glucose from 0 to 120 minutes; HOMA2, Homeostasis Model Assessment 2 to estimate model derived steady beta cell function (-B) and insulin sensitivity (-S); ISI, Insulin Sensitivity Index from Matsuda et al. (1000 / ([fasting glucose × fasting insulin] × [mean glucose x mean insulin])0.5; Insgen, Insulinogenic Index (insulin 30 min – insulin 0 min) / (glucose 30 min – glucose 0 min); af, female; m, male.